Aetna Modifies Pembrolizumab (Keytruda) Coverage Policy CPB 0890 — What Oncology Billing Teams Need to Know
Aetna, a CVS Health company, updated Clinical Policy Bulletin CPB 0890 covering pembrolizumab (Keytruda) and the newer subcutaneous formulation pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex), effective March 13, 2026. This modified policy governs one of the most widely billed oncology biologics in commercial plans, spanning dozens of tumor types and biomarker-driven indications. If your practice administers pembrolizumab under Aetna commercial plans, this update demands immediate attention from your prior authorization and coding teams.
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Pembrolizumab (Keytruda) — CPB 0890 |
| Policy Code | CPB 0890 |
| Change Type | Modified |
| Effective Date | 2026-03-13 |
| Impact Level | High |
| Specialties Affected | Medical Oncology, Radiation Oncology, Gynecologic Oncology, Hematology, Urology, Dermatology |
| Key Action | Review all active and pending Keytruda prior auth requests against updated biomarker and combination therapy criteria before March 13, 2026 |
Aetna Keytruda CPB 0890: Precertification Requirements
Precertification is required for all Aetna participating providers and members in applicable plan designs for both the IV formulation (Keytruda) and the subcutaneous formulation (Keytruda Qlex). There are no exceptions to this requirement.
To submit precertification requests:
- Phone: (866) 752-7021
- Fax: (888) 267-3277
- SMN Forms: Available via Aetna's Specialty Pharmacy Precertification portal
Additionally, Aetna's Site of Care Utilization Management Policy applies to both formulations. This means your team must confirm that the administration site meets Aetna's requirements before scheduling infusions or subcutaneous injections—site-of-care denials are a common and avoidable revenue cycle problem for high-cost biologics like pembrolizumab.
Aetna Pembrolizumab Coverage Criteria: Approved Indications Under CPB 0890
The policy outlines medical necessity criteria across a broad range of tumor types. Coverage is indication-specific, biomarker-driven in many cases, and often line-of-therapy-dependent. Below are the key approved indications from the updated policy:
Ampullary Adenocarcinoma
Covered as a single agent for MSI-H, dMMR, or TMB-H (≥10 mut/Mb) disease.
Anal Carcinoma
Covered as a single agent for subsequent treatment of metastatic anal carcinoma.
CNS Brain Metastases
Covered as a single agent for brain metastases in members with melanoma or PD-L1 positive non-small cell lung cancer (NSCLC).
Cervical Cancer
Three pathways to coverage:
| # | Covered Indication |
|---|---|
| 1 | Persistent, recurrent, or metastatic disease in combination with chemotherapy ± bevacizumab when PD-L1 CPS ≥1 |
| 2 | Recurrent or metastatic disease as a single agent or in combination with tisotumab vedotin-tftv when PD-L1 CPS ≥1, MSI-H, or dMMR |
| 3 | FIGO stage III–IVA disease in combination with chemoradiation |
Classic Hodgkin Lymphoma
Covered for relapsed or refractory disease in the following regimens:
| # | Covered Indication |
|---|---|
| 1 | Single agent |
| 2 | In combination with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) |
| 3 | In combination with ICE (ifosfamide, carboplatin, etoposide) |
| 4 | In combination with decitabine or vorinostat if refractory to at least three prior lines of therapy |
Cutaneous Melanoma
Four coverage pathways:
| # | Covered Indication |
|---|---|
| 1 | Unresectable or metastatic disease as a single agent |
| 2 | Subsequent therapy for disease progression as a single agent or in combination with ipilimumab or lenvatinib |
| 3 | Neoadjuvant treatment as a single agent |
| 4 | Adjuvant treatment following complete lymph node dissection |
Aetna Keytruda Exclusions: When Coverage Is Denied
Two categorical exclusions apply to all members, regardless of indication:
- Pediatric members with TMB-H central nervous system cancers — not eligible under any circumstance.
- Members who experienced disease progression on a PD-1 or PD-L1 inhibitor — not eligible, with one exception: subsequent therapy for metastatic or unresectable melanoma in combination with ipilimumab or lenvatinib.
The second exclusion is the one most likely to generate prior auth denials at the point of reauthorization. If a patient progressed on durvalumab, atezolizumab, or nivolumab—or on a prior course of pembrolizumab itself—your clinical documentation must clearly address this exclusion or the auth will not go through.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
Affected Codes
Covered Billing Codes
HCPCS Drug Administration Codes
| Code | Type | Description |
|---|---|---|
| J9271 | HCPCS | Injection, pembrolizumab, 1 mg |
| J0893 | HCPCS | Injection, decitabine (Sun Pharma), not therapeutically equivalent to J0894, 1 mg |
| J0894 | HCPCS | Injection, decitabine, 1 mg |
| J8522 | HCPCS | Capecitabine, oral, 50 mg |
| J8530 | HCPCS | Cyclophosphamide, oral, 25 mg |
| J8560 | HCPCS | Etoposide, oral, 50 mg |
| J8565 | HCPCS | Gefitinib, oral, 250 mg |
| J9022 | HCPCS | Injection, atezolizumab, 10 mg |
Chemotherapy Administration CPT Codes
| Code | Type | Description |
|---|---|---|
| 96413 | CPT | Chemotherapy administration, IV infusion; up to 1 hour, single or initial substance/drug |
| 96415 | CPT | Chemotherapy administration, IV infusion; each additional hour |
| 96416 | CPT | Chemotherapy administration, highly complex drug; initiation of prolonged infusion |
| 96417 | CPT | Chemotherapy administration, highly complex drug; each additional sequential infusion |
| 96401 | CPT | Injection, non-hormonal antineoplastic chemotherapy/highly complex drug |
| 96402 | CPT | Hormonal antineoplastic chemotherapy injection |
Diagnostic & Biomarker Testing CPT Codes
| Code | Type | Description |
|---|---|---|
| 81301 | CPT | Microsatellite instability (MSI) analysis |
| 81210 | CPT | BRAF gene analysis (e.g., colon cancer, melanoma) |
| 81235 | CPT | EGFR gene analysis, common variants |
| 88341 | CPT | Immunohistochemistry per specimen; each additional single antibody stain |
| 88342 | CPT | Immunohistochemistry per specimen; initial single antibody stain |
| 88360 | CPT | Morphometric analysis, tumor immunohistochemistry (e.g., Her-2/neu, ER/PR) |
| 88361 | CPT | Morphometric analysis using computer-assisted technology |
Radiation Treatment Management CPT Codes
The policy references CPT codes 77427–77470 (radiation treatment management) in the context of TMB-H and POLD indications. These codes cover the full range of radiation treatment management visits associated with pembrolizumab combination chemoradiation protocols.
Related ICD-10 Diagnosis Codes
The policy references 1,324 ICD-10-CM codes. Given the breadth of approved indications—spanning cervical cancer, melanoma, NSCLC, Hodgkin lymphoma, ampullary adenocarcinoma, CNS metastases, and anal carcinoma—your coding team should confirm the full ICD-10 crosswalk against the active policy at PayerPolicy CPB 0890.
What Your Billing Team Should Do
| # | Action Item |
|---|---|
| 1 | Audit all active Keytruda prior authorizations before March 13, 2026. Compare the approved indication and combination regimen against the updated criteria in CPB 0890. Any patient currently on a PD-1/PD-L1 inhibitor or who progressed on one previously is a high-risk account for denial at reauthorization. |
| 2 | Verify Keytruda Qlex (subcutaneous) is on your chargemaster and PA workflow. The updated policy explicitly covers pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) as a distinct product. If your practice has started transitioning patients to the subcutaneous formulation, confirm that your PA team is submitting under the correct drug name and that J9271 is mapped appropriately. |
| 3 | Confirm biomarker documentation is in the chart before submitting PA. MSI-H, dMMR, TMB-H (≥10 mut/Mb), PD-L1 CPS scores, and FIGO staging are required depending on the indication. Missing or ambiguous biomarker results are the single fastest path to a medical necessity denial. CPT codes 81301 (MSI analysis), 88342, and 88360 (IHC) should be reflected in the chart before the auth request goes in. |
| 4 | Flag all pediatric patients with CNS tumors. The TMB-H pediatric CNS exclusion is categorical—no prior auth will be approved for this population. Catching this before submission saves time and protects patient access to alternative therapies. |
| 5 | Review your site-of-care documentation. Aetna's Site of Care UM Policy applies to both Keytruda and Keytruda Qlex. Ensure your infusion or injection site meets Aetna's criteria and that this is documented in the auth request. Failure here results in payment denial even when the drug indication is covered. |
| 6 | Update denial management protocols for PD-1/PD-L1 prior therapy. Train your appeals team on the narrow exception that applies—metastatic or unresectable melanoma patients can receive pembrolizumab as subsequent therapy in combination with ipilimumab or lenvatinib after PD-1/PD-L1 progression. This is the only scenario where a documented progression on checkpoint inhibitor therapy does not trigger automatic exclusion. |
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.